This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on ISI (1)  • Contact me when this article is cited  Related Content  • Related article  • Similar articles in this journal  Topic Collections  • HIV/AIDS  • Phototherapy  • Alert me on articles by topic

Arch Dermatol. 1998;134:1025-1026.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

EVER SINCE it was shown that UV radiation activates the human immunodeficiency virus (HIV) in vitro,^1-2 the possibility that UV therapies may affect the progression of HIV disease has attracted the attention of clinicians and laboratory scientists. Additional in vitro and animal studies conducted using HIV promoter/reporter gene constructs³ made it possible to determine types of UV exposure and dose ranges that have HIV-activating potential. Both basic dermatologic UV modalities, UV-B and psoralen–UV-A (PUVA), were found to activate HIV or its promoter. Analyses of the laboratory data suggest that during clinical exposures, HIV-activating UV-B doses can be delivered to the outer layers of the skin, but not to the blood.³ This conclusion finds support in a recent report by Simpson et al,⁴ who found that a single exposure to 100 to 300 J/m² of UV-B radiation increased the HIV load 5- to 10-fold in biopsy specimens taken from psoriatic and . . . [Full Text of this Article]

RELATED ARTICLE

Effect of UV-B Phototherapy on Plasma HIV Type 1 RNA Viral Level: A Self-controlled Prospective Study
Joel M. Gelfand, Donald Rudikoff, Mark Lebwohl, and Mary E. Klotman
Arch Dermatol. 1998;134(8):940-945.
ABSTRACT | FULL TEXT